Trevaclyn
Withdrawn
This medicine's authorisation has been withdrawn
laropiprant / nicotinic acid
MedicineHumanWithdrawn
Greek is available via eTranslation, the European Commission's machine translation service.
Translate to Greek | Important information about machine translation
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
On the 3 July 2008 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal products Trevaclyn (nicotinic acid/laropiprant), which had been approved for the treatment of dyslipidaemia, particularly in adult patients with combined mixed dyslipidaemia (characterised by elevated levels of LDL-cholesterol and triglycerides and low HDLcholesterol) and in adult patients with primary hypercholesterolaemia (heterozygous familial and nonfamilial).
The marketing authorisation holder (MAH) responsible for Trevaclyn was Merck Sharp & Dohme Ltd. The European Commission was notified by a letter dated 20 March 2013 of the MAH’s decision to voluntarily withdraw the marketing authorisations. This followed the CHMP’ recommendation to suspend the marketing authorisations of these products on 17 January 2013. None of the products are currently marketed in any EU country.
On 10 April 2013 the European Commission issued a decision to withdraw the marketing authorisations for Trevaclyn.
Pursuant to this decision the European Public Assessment Reports for Trevaclyn is updated to reflect the fact that the marketing authorisations are no longer valid.
Product information
Latest procedure affecting product information:A20/0038
10/04/2013
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Trevaclyn
- Active substance
- laropiprant
- nicotinic acid
- International non-proprietary name (INN) or common name
- laropiprant
- nicotinic acid
- Therapeutic area (MeSH)
- Dyslipidemias
- Anatomical therapeutic chemical (ATC) code
- C10AD52
Pharmacotherapeutic group
Lipid modifying agentsTherapeutic indication
Trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).
Trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol-lowering effect of HMG-CoA-reductase-inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Trevaclyn.
Assessment history
News on Trevaclyn
This page was last updated on